Ischemic Heart Disease (IHD) Drugs Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Ischemic Heart Disease (IHD) Drugs Market?
The surge in obesity and diabetes cases is anticipated to spur the expansion of the ischemic heart disease (IHD) drugs market. Diabetes, a chronic metabolic condition that results in elevated blood glucose levels, and obesity, a health condition marked by excessive body fat accumulation, adversely affecting wellbeing, frequently necessitate the use of ischemic heart disease medications. This is particularly so in managing cardiovascular risk factors such as hypertension and dyslipidemia, which subsequently abate the risk of ischemic heart disease. For example, the World Obesity Federation, a UK outfit spearheading global initiatives to curb, prevent and address obesity, forecasted that by 2030, one billion people all over the world, including one in five women and one in seven men, will be obese. Additionally, in June 2024, the UK’s National Health Service indicated that in 2023, an additional 549,000 individuals in England were identified as at risk of developing type 2 diabetes, which increased the total number of pre-diabetic individuals, registered with a GP, to 3,615,330, denoting a nearly 20% rise compared to 3,065,825 in 2022. Hence, the escalating prevalence of obesity and diabetes is fuelling the growth of the ischemic heart disease (IHD) drugs market.
Rising Instances of Heart Failure Catalyze Ischemic Heart Disease (IHD) Drugs Market Growth
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp
#What Growth Opportunities Will Drive the Ischemic Heart Disease (IHD) Drugs Market’s CAGR Through 2034?
The market size for drugs targeting ischemic heart disease (IHD) has experienced substantial growth recently. There is an expected growth from $6.36 billion in 2024 to $6.71 billion in 2025, showing a compound annual growth rate (CAGR) of 5.6%. Factors contributing to the growth observed in the past years include a worldwide increase in ischemic heart disease cases, enhanced consciousness and diagnostic procedures, lifestyle and dietary changes, government cardiovascular health programs, collaboration on clinical trials, and stipulations regarding insurance coverage and reimbursements.
Expectations are that the Ischemic Heart Disease (IHD) drugs market will experience consistent growth in the coming years, reaching a value of $7.86 billion by 2029. This represents a compound annual growth rate (CAGR) of 4.0%. Various factors contribute to this projected growth over the forecast period including demographic aging, personalization of medicine, a focus on cardiovascular prevention, international health policies and partnership initiatives, and global research collaborations. Key trends for this period are the transition to precision medicine, development of innovative anti-atherogenic agents, advancements in therapies lowering lipid levels, incorporation of anti-inflammatory agents, and the cultivation of antithrombotic and antiplatelet drugs.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13467
What Are the Key Market Innovations in theIschemic Heart Disease (IHD) Drugs Market Over the Coming Years?
Key players in the ischemic heart disease (IHD) drugs market are ramping up efforts to devise innovative myosin inhibitors to secure a leading position in the market. Cardiac myosin inhibitors are drugs that hinder myosin activity in cardiac muscles, thereby reducing contraction force. These inhibitors are particularly beneficial for heart conditions like hypertrophic cardiomyopathy (HCM) characterized by an abnormal thickening of the heart muscle, which hinders its functioning. To illustrate, Bristol Myers Squibb, a pharmaceutical company based in the US, launched Camzyos (mavacamten) in April 2022. This medication, the first of its kind designed for cardiac myosin inhibition, received approval for treating adults suffering from symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy (HCM), enhancing functional capacity and relieving symptoms. As an allosteric and reversible inhibitor exclusive to cardiac myosin, the drug diminishes hypercontractility and left ventricular hypertrophy while enhancing cardiac filling pressures. This, in turn, helps reduce dynamic left ventricular outflow tract (LVOT) obstruction.
Who Are the Top Companies Driving Innovation and Growth in theIschemic Heart Disease (IHD) Drugs Market?
Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC
Order Your Report Now For A Swift Delivery:
Which Key Market Segments Comprise the Ischemic Heart Disease (IHD) Drugs Market and Drive Its Revenue Growth?
The ischemic heart disease (IHD) drugs market covered in this report is segmented –
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp
Which Regions Are Emerging as Leaders in the Ischemic Heart Disease (IHD) Drugs Market?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global Ischemic Heart Disease (IHD) Drugs Market 2025, By The Business Research Company:
Narcotic Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/narcotic-drugs-global-market-report
Preeclampsia Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report
Congenital Diaphragmatic Hernia Drugs Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
